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Abstract
Background: Between 2003 and 2010 digital mammography (DM) gradually replaced screen-film mammography
(SFM) in the Dutch breast cancer screening programme (BCSP). Previous studies showed increases in detection rate
(DR) after the transition to DM. However, national interval cancer rates (ICR) have not yet been reported.
Methods: We assessed programme sensitivity and specificity during the transition period to DM, analysing nationwide
data on screen-detected and interval cancers. Data of 7.3 million screens in women aged 49–74, between 2004 and
2011, were linked to the Netherlands Cancer Registry to obtain data on interval cancers. Age-adjusted DRs, ICRs and
recall rates (RR) per 1000 screens and programme sensitivity and specificity were calculated by year, age and
screening modality.
Results: 41,662 screen-detected and 16,160 interval cancers were analysed. The DR significantly increased from 5.13
(95% confidence interval (CI):5.00–5.30) in 2004 to 6.34 (95% CI:6.15–6.47) in 2011, for both in situ (2004:0.73;2011:1.24)
and invasive cancers (2004:4.42;2011:5.07), whereas the ICR remained stable (2004: 2.16 (95% CI2.06–2.25);2011: 2.13
(95% CI:2.04–2.22)). The RR changed significantly from 14.0 to 21.4. Programme sensitivity significantly increased, mainly
between ages 49–59, from 70.0% (95% CI:68.9–71.2) to 74.4% (95% CI:73.5–75.4) whereas specificity slightly declined
(2004:99.1% (95% CI:99.09–99.13);2011:98.5% (95% CI:98.45–98.50)). The overall DR was significantly higher for DM than
for SFM (6.24;5.36) as was programme sensitivity (73.6%;70.1%), the ICR was similar (2.19;2.20) and specificity was
significantly lower for DM (98.5%;98.9%).
Conclusions: During the transition from SFM to DM, there was a significant rise in DR and a stable ICR, leading
to increased programme sensitivity. Although the recall rate increased, programme specificity remained high
compared to other countries. These findings indicate that the performance of DM in a nationwide screening
programme is not inferior to, and may be even better, than that of SFM.
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Background
Sensitivity and specificity are considered to be important
quality assurance indicators for the performance of
screening. The sensitivity of a breast cancer screening
programme (BCSP) is calculated using the detection rate
(DR) of screen-detected cancers and the interval cancer
rate (ICR). The number of published studies that report
interval cancers on a national level is scarce [1–4]. Data
on nationwide interval cancers are difficult to obtain, as
an accurate linkage between national screening data and
the national cancer registry is required. In addition, be-
cause the number of interval cancers can only be deter-
mined at the end of an interval between screening
rounds, there is an inherent delay in the availability of
the data (usually two years), compared to data on can-
cers detected at screening.
In the past decade, many Western BCSPs made the
transition from screen-film mammography (SFM) to
digital mammography screening (DM) [5–9]. DM has
been shown to influence the performance of BCSPs,
leading to higher detection rates than SFM, through in-
creased recall rates [6, 10–13]. In most studies, the in-
crease in cancer detection was largely driven by a
significant rise in the detection of DCIS. It has been ar-
gued that increased DCIS detection leads to a substantial
rise in overdiagnosis of breast cancer without contribut-
ing to breast cancer mortality reduction. However, a re-
cently published study showed an association between
increased screen-detection of DCIS and fewer subse-
quent invasive interval cancer cases [14]. DM may thus
also have the potential to lower ICRs.
In the Netherlands, the transition from SFM to DM
was realised between 2003 and 2010 [15, 16]. In the
same period, the percentage of 2-view mammography at
subsequent screens increased from 50% to over 90%
[17, 18]. Several Dutch studies showed statistically
significant improvements in cancer detection for DM
compared to SFM [13, 19–22], whereas others found
no significant differences [16, 23]. However, so far,
only regional interval cancer rates during the transi-
tion to DM in the Netherlands have been published
[16, 21] and programme sensitivity on a national level
was therefore not calculated.
The objective of this study was to evaluate the national
performance of the BCSP in the Netherlands during the
transition period to DM by assessing programme sensi-
tivity and specificity, using screen-detected and interval
cancers between 2004 and 2011.
Methods
Dutch breast cancer screening programme
The Dutch BCSP is carried out by 5 regional Cancer
Screening Organisations (65 screening units), which in-
vite all eligible women based on the population registry,
aged 50–74 years, biennially to take part in screening.
The attendance rate is around 80%. From 2003 onwards,
a pilot phase started in which DM was introduced next
to SFM, increasing the proportion of DM from 1% to 7%
of all screens in 2007. This period was followed by a
roll-out phase in which DM expanded from 10% in
2008, to 42% in 2009 and 100% in June 2010.
We collected data on all screens between 2004 and
2011. At initial screens 2-view mammography, with
double reading, was performed. In 2004, about half of
the subsequent screens had a second view and this pro-
portion increased to 93% in 2010. The reading policy
was double reading with consensus or arbitration.
Women were only recalled if both independent readers
concluded that the screening mammogram was positive
or if a third reader came to this conclusion, in case of
disagreement.
Data
All screen-detected and interval cancers between 2004
and 2011 were analysed. To classify cancers as screen-
detected or interval cancers, records of all screening ex-
aminations were linked to the Netherlands Cancer Regis-
try (NCR). Linkages were made using an algorithm to
identify identical subjects with high probability. The NCR
classified the positive matches (94% of all breast cancers)
preliminarily into screen-detected and interval cancers.
Unclassified cancers were checked manually by the Cancer
Screening Organisations, using information from the pa-
tient’s medical file. A small fraction of all women screened
(0.01%) did not give permission to link their records.
Information on whether DM or SFM was performed
was derived from the separate screening units, following
the rollout schedule for digitization.
Definitions
Screening examinations were defined as mammograms
following an invitation to screening. These examinations
were subdivided in initial screens, regular subsequent
screens within 2.5 years after previous screening and ir-
regular subsequent screens 2.5 years or later after previ-
ous screening (4% of all screens between 2004 and
2011). The latter were not used in this study: as the pre-
cise length of the irregular interval could not be deter-
mined from the aggregated dataset, including irregular
subsequent screens would lead to distortion of (i.e.
higher) detection- and interval cancer rates. Positive
screens were considered to be screens with a suspicious
mammographic lesion leading to recall and negative
screens those without suspicious mammographic lesions,
without any recommendation. Thus, screen-detected
breast cancers were all diagnosed as a direct conse-
quence of recall for further assessment, within one year
after a positive screen.
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All breast cancers diagnosed within two years after a
negative screen were considered to be interval cancers.
This concerned cancers arising from:
– Lesions that were screen-detectable at time of
screening but were missed or not recalled
– Lesions that were present at screening but had
minimal signs and were not recalled
– Lesions that were not present at screening and
emerged within the screening interval
Interval cancers could also occur after a false-positive
screen: if the cancer detected in the interval did not re-
semble the earlier detected lesion or was localized in the
other breast, it was considered to be an interval cancer
and coded accordingly. Interval cancers were thus calcu-
lated using all screens and not only women with a nega-
tive screen.
Both ductal carcinomas in situ (DCIS) and invasive
cancers were included in the number of screen-detected
and interval cancers.
We defined programme sensitivity as the number of
screen-detected cancers expressed as a proportion of the
total number of breast cancers diagnosed in women who
were screened, within two years after screening (screen-
detected cancers + interval cancers). Programme specifi-
city was defined as the number of negative screens in
women without breast cancer as a proportion of the
total number of screens in women without a breast can-
cer diagnosis (true negatives + false-positives), within
two years after screening. The false-positive rate was cal-
culated as the number of recalls that did not lead to a
breast cancer diagnosis per 1000 screens. As for some
recalls the final diagnosis is not known, the numbers of
true- and false-positives do not completely add up to the
number of recalled women.
Age-adjusted recall (RR), false-positive (FPR), detec-
tion (DR) and interval cancer rates (ICR) per 1000
screens were calculated, using the total number of invi-
tations during 2004–2011 as reference population. The
positive predictive value (PPV) was calculated as the per-
centage screen-detected cancers (true positives) of all
women recalled (true and false-positives). Perform-
ance indicators were based on all screening examina-
tions (initial + regular subsequent), calculated by
calendar year and age and presented with 95% confi-
dence intervals (CI).
Analysis
Screening examinations performed at age 75 (N = 9507)
and interval cancers diagnosed within two years after
screening at age 75 (N = 16) were excluded because of
small numbers. Results are presented for the age group
49–74 and were calculated for the period 2004–2011,
for all screening examinations and for DM and SFM
screens separately.
Whether differences in outcomes were statistically sig-
nificant was determined using the 95% confidence inter-
vals. For proportions these intervals were calculated
using the standard formula (P ± 1.96*s.e.). The 95% con-
fidence intervals for the rates were calculated using a log
linear model (exp(β+ log(N)); Poisson distribution) and
rates were calculated per 1000 screens.
Results
All screens
Overall results
Between 2004 and 2011, 7,343,327 screens (initial +
regular subsequent) were performed within the Dutch
BCSP (Table 1). There were 41,662 breast cancers de-
tected by screening; the DR was 5.7 per 1000 screens, of
which 0.94 were DCIS. The recall rate (RR) was 17.8 per
1000 screens and the FPR 12.1 (PPV:33.5%). The 16,160
interval cancers identified led to an ICR of 2.2 per 1000,
of which 0.1 were DCIS (Additional file 1: S3). The
programme sensitivity was 71.4% and the programme
specificity 98.8%.
Trends over time
The DR significantly increased by more than 20% over
the study period, from 5.1 per 1000 to 6.3 and the ICR
remained stable (Fig. 1a; Additional file 1: S1a). The
DRs of both DCIS (+ 0.5) and invasive breast cancers
(+ 0.7) increased (Additional file 1: S1a). The detection
rate increased for all age groups over the entire study
period (Fig. 2a; Additional file 1: S2a). Detection also
increased with age from 55 years onward; in the youn-
gest ages (in particular 49 years) the detection rate was
relatively high due to prevalent screening.
The overall ICR remained stable over the study
period (2004: 2.2 per 1000 screens; 2011: 2.1; Fig. 1a;
Additional file 1: S1a). The interval cancer rate
showed a slightly decreasing tendency for the younger
age groups over the study period and a slight increase in
the trend for the older ages (Fig. 2b; Additional file 1:
S2b). The fluctuation in the overall interval cancer rate
was mainly determined by the rate for invasive breast can-
cers (Fig. 3). There were slight decreases in the age-
adjusted overall interval cancer rate in 2007, 2009 and
2011 relative to the previous year (not statistically signifi-
cant), accompanied by a decline in invasive interval can-
cers alone in 2007 and in both invasive and in situ interval
cancers in 2009 and 2011 (Fig. 3; Additional file 1: S3).
The programme sensitivity increased from 70.0% in
2004 to 74.4% in 2011 (Fig. 4a; Additional file 1: S1a)
and increased statistically significant from 2010 (com-
pared to 2004). The overall programme sensitivity
was mainly determined by SFM between 2004 and
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2008 and increased steeply with the expansion of
DM between 2008 and 2011 (Fig. 4a; Additional file 1:
S1b, S1c). The programme sensitivity strongly varied
by age in 2004, which attenuated with the expansion
of DM due to a significant increase in programme
sensitivity for women aged 49–59 (Add-
itional file 1: S4). Trends in programme sensitivity of
all breast cancers and invasive cancers only were
similar between 2004 and 2008 (Fig. 5). In 2009–
2010, there was an increase in the sensitivity of all
cancers but not of invasive cancers only, which re-
flects an increased detection of DCIS. In 2011, there
was a similar rise in both groups, thus reflecting an
increased detection of invasive cancers.
The RR increased significantly over time from 14.0 to
21.4 (Additional file 1: S1a). The programme specificity
significantly declined slightly from 99.1% to 98.5%
(Fig. 4b; Additional file 1: S1a). The difference in
programme specificity between DM and SFM was
most prominent in the beginning of the study period
and decreased over time.
DM versus SFM
Overall results
Of all screens, 2,620,442 were DM (36%) and 4,722,885
SFM (64%; Table 1). The RR for DM was 1.3 times
higher than the RR for SFM. The DR was significantly
higher for DM than for SFM (6.2 vs. 5.4), leading to
higher programme sensitivity (73.6% vs. 70.1%). Both the
DR of DCIS and invasive cancers were significantly
higher for DM (1.1 and 5.1 respectively) than for SFM
(0.83 and 4.5) (Table 1). The PPV and programme speci-
ficity were significantly lower for DM (31.5% and 98.5%
respectively) than for SFM (34.9% and 98.9%). The ICRs
were equal (2.2).
a b
Fig. 1 Age-adjusted detection and interval cancer rates per 1000 women screened for all screens (a) and DM or SFMa (b) (49–74). aIn 2011 all
screens were DM screens. Abbreviations: detection rate (DR); interval cancer rate (ICR); digital mammography (DM); screen-film mammography (SFM)
Table 1 Age-adjusted results for all, DM and SFM examinations between 2004 and 2011 (49–74)
All (95% C.I.) DM (95% C.I.) SFM (95% C.I.)
No. screens 7,343,327 2,620,442 4,722,885
No. screen-detected cancers 41,662 16,400 25,262
No. interval cancers 16,160 5748 10,412
No. false-positives 88,862 38,621 50,241
No. recalls 130,524 55,021 75,503
Recall rate 17.8 (17.7–17.9) 21.0 (20.8–21.2) 16.0 (15.9–16.1)
False positive rate 12.1 (12.0–12.2) 14.8 (14.7–15.28) 10.6 (10.5–10.7)
Detection rate (all) 5.7 (5.6–5.7) 6.2 (6.1–6.3) 5.4 (5.3–5.4)
Detection rate DCIS 0.94 (0.92–0.96) 1.1 (1.1–1.2) 0.83 (0.81–0.86)
Detection rate invasive 4.7 (4.7–4.8) 5.1 (5.0–5.2) 4.5 (4.5–4.6)
Interval cancer rate 2.2 (2.2–2.2) 2.2 (2.1–2.3) 2.2 (2.2–2.3)
Programme sensitivity (%) 71.4 (71.1–71.8) 73.6 (73.0–74.2) 70.1 (69.6–70.6)
Programme specificity (%) 98.8 (98.8–98.8) 98.5 (98.5–98.5) 98.9 (98.9–98.9)
Positive predictive value (%) 33.5 (33.2–33.7) 31.5 (31.1–31.9) 34.9 (34.5–35.2)
Rates are presented per 1000 screens
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Trends over time
The DR of DM was higher than that of SFM in all years,
and significantly higher in 2004, 2007 and 2009 (Fig. 1b;
Additional file 1: S1b, S1c). The ICRs were similar over
the years (except for 2004).
Discussion
This nationwide study shows that the detection rate and
programme sensitivity in the Dutch BCSP significantly
increased during the transition from SFM to DM. This
rise was most prominent for women under age 60. Des-
pite the substantial improvement in detection, there was
no decrease in the overall ICR. The programme specifi-
city declined slightly as a result of the increased recall
rate. Slight decreases were observable in the trend in
interval cancers for younger women. The detection of
both DCIS and invasive cancers and programme sensi-
tivity were significantly higher for DM than for SFM,
whereas the ICR was similar and the programme specifi-
city was slightly lower for DM.
The increase in cancer detection can be partially ex-
plained by the transition to DM. Other studies also re-
ported higher DRs for DM [6, 10, 12, 13]. DM has been
demonstrated to lead to a substantially higher DCIS
detection compared to SFM in the Netherlands [13, 20,
22]. There have been concerns that the increase in screen-
detection of DCIS leads to overdiagnosis rather than to a
significant additional reduction in breast cancer mortality
[24]. Therefore, some might argue that the rise in breast
cancer detection in this study largely reflects overdiagno-
sis. However, results of a recent study suggest that for
every 1.5–3 screen-detected DCIS cases, one subsequent
invasive interval cancer is averted; at levels of DCIS up to
1.5 per 1000 women screened (0.94 in our study) [14]. In
addition, our findings show a significant increase in the
detection of invasive breast cancers, which are less likely
to be overdiagnosed than DCIS. Nevertheless, we
recognize that a substantial rise in cancer detection may
lead to a somewhat higher absolute number of overdiag-
nosed cases. Next to the transition to DM however, other
factors also contributed to the increase in breast cancer
detection. This increase already started in the mid-1990s,
far before the introduction of DM [18]. First, the higher
DR may also have resulted from an increase in the under-
lying breast cancer incidence over the years. It has been
shown that the underlying breast cancer incidence in the
Netherlands increased before the introduction of screen-
ing between 1975 and 1990 in women later invited to
a b
Fig. 2 Age-specific detection (a) and interval cancer rates (b) per 1000 women screened
Fig. 3 Age adjusted-interval cancer rate (per 1000 women screened) for all, invasive and in situ carcinomas
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screening and in women not yet invited to screening
(40–49) before and after the introduction of screening
(1975–2004) [25], which has also been reported for
other countries [26, 27]. It is reasonable to expect
that the rise in background incidence continued after
implementation of screening, due to increases in risk
factors for breast cancer, including older age at first
pregnancy and menarche and breast feeding at a later
stage in life [28–30]. For example, in the Netherlands,
the average age at birth of first child has increased
from 26 years in 1970 to 29 years in 2004 [31].
Second, the significant increase in the percentage of 2-
view mammography at subsequent screens during our
study period (50% in 2005; > 90% in 2011 [18]) is likely
to have contributed to higher breast cancer detection
[17, 32, 33]. Finally, the DR may have increased due to
changes in screening protocol. Following the outcomes
of a study by Otten et al. [34], the national recall strategy
was altered and the RR in the Netherlands increased
from 0.9% in 2000 to 1.8% in 2007 [18].
We think that the stable interval cancer rate with the
increasing trend in detection could also in fact reflect a
reduction in the ICR, given the increase in background
breast cancer incidence. The rise in detection may have
prevented the interval cancer rate to increase as a result
of increased breast cancer incidence.
Our estimate for the overall ICR (2.2 per 1000 screens)
is in line with earlier reported rates from the BCSP in
Germany (2.3) [35] and Norway (1.8) [2].
We found that DM performed significantly better than
SFM in terms of DR and programme sensitivity, at the
expense of significantly higher RRs and FPRs and slightly
lower programme specificity. These findings are also
consistent with results of earlier studies [6, 10, 12, 13, 19] .
We found RRs (expressed as the percentage of screens
recalled for further assessment) of 1.6% for SFM and 2.1%
for DM throughout the study period. Recently reported
RRs for DM in other European BCSPs range from 2.9% to
6.1% [5–7, 9, 36, 37]. Therefore, RRs in the Netherlands
are still rather low compared to other countries [6, 12, 36,
38].
We did not find a difference in ICR between DM and
SFM. Similar ICRs for DM and SFM were also reported
for other BCSPs [37, 39]. It might be too early to
a b
Fig. 4 Aged-adjusted programme sensitivity (a) and programme specificity (b) for all screens, DMa and SFM (49–74). aThe percentage DM screens
between 2004 and 2007 was considerably small; in 2011, all screens were DM screens. N.B. scale Y-axis differs between graph a and b. Abbreviations:
digital mammography (DM); screen-film mammography (SFM)
Fig. 5 Age-adjusted programme sensitivity for all (invasive + DCIS) and invasive breast cancers only (49–74)
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observe the full effect of the transition to DM on the
ICR. We observed a small, non-significant, decrease in
the overall ICR in 2011 but we need future data, after a
few years of full DM screening, to determine whether or
not this will turn into a further statistically significant
decline. Although we did not observe a significant differ-
ence in the overall ICR, looking at specific age groups
we found that the ICR at initial screening in women aged
49–51 years was significantly lower for DM than for SFM
(2.3 vs. 2.6 per 1000 screens; Additional file 1: S5). This
finding corresponds to the results of the DMIST trial,
which showed a higher diagnostic accuracy for DM than
for SFM in pre- and perimenopausal women with dense
breasts under the age of 50 [10].
The major strength of this study was the availability of
national data on a large number of interval cancers.
Thus, this study is the first nationwide analysis of sensiti-
vity and specificity in the Dutch BCSP during the transition
to DM. Furthermore, DM expanded during the second half
of the study period and the effect of the transition from
SFM to DM could therefore be studied well.
This study also had some limitations. Single screening
examinations were not labelled as DM or SFM at time
of screening and information about the proportion DM
and SFM, during the years in which both modalities
were used, had to be obtained from the screening units.
The screens for which it was uncertain whether they
were performed using screen-film or digital mammog-
raphy were added to the screen-film group. This could
lead to underestimation of detection rates for DM and
to increased apparent detections rates for SFM. The dif-
ference in detection of DM relative to SFM could thus
be (somewhat) greater than we report and our estimates
may therefore be conservative. In addition, 2% of all
breast cancers in the NCR database could not be classi-
fied as screen-detected or interval cancer.
Conclusions
In conclusion, the detection rate in the Dutch breast
cancer screening programme substantially increased be-
tween 2004 and 2011, whereas the interval cancer rate
was stable over time. The recall rate increased over the
study period, resulting in a decrease in programme spe-
cificity over time, even though the current specificity of
the Dutch programme is still relatively high (in inter-
national context). DM resulted in higher detection rates
than SFM, with similar interval cancer rates. The overall
interval cancer rate, slightly, but non significantly de-
clined in younger age groups and a significant rise in
programme sensitivity in women under age 60 years was
observed, which may be partly attributable to the transi-
tion to DM. Particularly young women may therefore
have benefited from the change to DM but further ex-
ploration is needed to confirm these findings.
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